48TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 INTERVIEW CEO Enantia COO Enantia CCO Enantia Enantia was recently acquired by INVACO. How do you see this acquisition shaping the future direction of Enantia and what synergies do you anticipate between the two companies? This acquisition is very good news for Enantia as, on one hand, it will allow Enantia to move forward with a well-defined and ambitious business plan by itself and, on the other hand, it will allow a build-up of complementary small companies that will create a synergic effect around Enantia. This will translate into a more complete offering of services, which will cover a wider part of the drug discovery and development journey for our customers. With the acquisition by INVACO, Enantia is poised for further growth. What specific areas of Enantia poised for growth
RkJQdWJsaXNoZXIy MjY2OTA4MA==